FARALLON CAPITAL MANAGEMENT LLC
Position in BCRX — Biocryst Pharmaceuticals Inc
CIK 909661
SAN FRANCISCO, CA
Position in BCRX
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$228,480
+$41,280 QoQ
Shares Held
24,000
0.0% QoQ
Ownership
0.009%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2025
3 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in BCRX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026FARALLON CAPITAL MANAGEMENT LLC holds $762,985,549 across 10 Drug Manufacturers - Specialty & Generic names. BCRX ranks #6 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LNTH |
Lantheus Holdings, Inc.
|
5,583,479 | $423,506,882 | |
| 2 | LQDA |
Liquidia Corp
|
8,656,038 | $326,678,874 | |
| 3 | TEVA |
Teva Pharmaceutical Industries Ltd
|
354,000 | $10,662,480 | |
| 4 | ALKS |
Alkermes plc.
|
20,800 | $735,488 | |
| 5 | ALVO |
Alvotech
|
199,675 | $684,885 | |
| 6 | BCRX |
Biocryst Pharmaceuticals Inc
This page
|
24,000 | $228,480 | |
| 7 | HIMS |
Hims & Hers Health, Inc.
|
10,000 | $207,600 | |
| 8 | SUPN |
Supernus Pharmaceuticals, Inc.
|
4,000 | $206,760 |
All Filings in BCRX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $228,480 | 24,000 | Shares | Other | 2026-05-15 | |
| 2025-12-31 | $187,200 | 24,000 | Shares | Other | 2026-02-17 | |
| 2025-09-30 | $182,160 | 24,000 | Shares | Other | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||